SENZIME AB ORD - SNZZF STOCK NEWS

Senzime AB (STO:SEZI)(OTCQX:SNZZF) has released its interim report for January - June 2024, showing strong sales growth, particularly in the US market. Key highlights include:

- Net sales increased by 76% to TSEK 14,917 in Q2 2024
- US net sales grew by 167% to TSEK 10,973 in Q2 2024
- Disposable sensor sales rose by 92% to TSEK 8,412 in Q2 2024
- Gross margin before depreciation was 63.3% in Q2 2024
- Cash and cash equivalents stood at TSEK 80,184 as of June 30th

CEO Philip Siberg noted the company's success in gaining market share and establishing its technology as the new clinical standard in operating rooms worldwide. The expanded US sales organization has proven effective, with increased system utilization and nearly doubled disposable sensor deliveries compared to the previous year.

Senzime (STO:SEZI)(OTCQX:SNZZF) has announced a webcast presentation of its second quarter 2024 report scheduled for August 26, 2024, at 11:00 CEST. The report will be published earlier the same day. CEO Philip Siberg will lead the presentation, followed by a Q&A session moderated by Erik Palin, an analyst at Carnegie Investment Bank. The event will be conducted in English and can be accessed via Senzime's investor website. Investors, analysts, and media are invited to participate, with the option to submit questions in advance to klas.palin@carnegie.se. The presentation will also be available for later viewing on Senzime's website.

Senzime (STO:SEZI)(OTCQX:SNZZF) has expanded its contract with a top-10 ranked Integrated Delivery Network (IDN) healthcare system in the Southeastern United States. The new agreement extends TetraGraph monitor usage into adult care, following successful implementation in pediatric surgeries. This expansion will increase annual volumes fourfold, with 75 TetraGraph systems to be installed in operating rooms for monitoring both adults and children.

The contract reinforces Senzime's position as a trusted vendor in the US market, particularly as hospitals adopt new practice recommendations mandating quantitative neuromuscular monitoring. Senzime's TetraGraph system is used in hundreds of leading hospitals worldwide, helping anesthesiologists accurately manage neuromuscular blocking drugs and ensure safe patient recovery post-surgery.

Senzime (STO:SEZI) (OTCQX:SNZZF) announced that the European Patent Office has granted a new patent for its TetraGraph system, which enhances the device's noise-cancelling technology. This system is pivotal for monitoring patients who receive neuromuscular blocking drugs during anesthesia, ensuring accurate EMG-based signals by mitigating external noise. The TetraGraph system is used globally by anesthesiologists for precise drug dosing and timing of extubation, further establishing Senzime's leadership in patient monitoring. This marks an addition to Senzime's extensive portfolio of over 90 patents, reinforcing its commitment to innovation and patient safety.

Senzime (OTCQX:SNZZF) has secured a purchasing contract with the top-ranked children's hospital system in the US for its TetraGraph® neuromuscular monitoring system.

The system will be used in over 40 operating rooms, supporting more than 30,000 surgeries annually. The contract, awarded after a competitive evaluation, reinforces Senzime's position as a leader in quantitative train-of-four monitoring.

The TetraGraph system is already used by anesthesiologists in hundreds of leading hospitals globally and meets US and European clinical guidelines. The US market for quantitative monitoring is growing rapidly, and Senzime aims to capitalize on this trend.

A recent study published in the journal Anesthesiology confirms the leading accuracy and precision of Senzime's TetraGraph system. The study, conducted by US-based researchers, compared neuromuscular block monitors and found that Senzime's EMG-based TetraGraph system outperformed AMG-based monitors, aligning closely with a gold-standard laboratory reference. The American Society of Anesthesiologists (ASA) and the European Society of Anaesthesiology and Intensive Care (ESAIC) have recommended routine use of quantitative neuromuscular monitoring, emphasizing the importance of systems like TetraGraph. CEO Philip Siberg highlights that this study could solidify TetraGraph's role as the clinical standard, noting its minimal measurement variability and ease of use compared to AMG-based monitors.

Senzime (STO:SEZI)(OTCQX:SNZZF), a leading provider of perioperative precision-based patient monitoring solutions, has appointed Dr. Wolfgang Reim as the new senior advisor to its Board of Directors. Dr. Reim brings extensive experience from his previous roles, including CEO of Dräger Medical and the Ultrasound Division at Siemens Healthcare. His background includes serving on the boards of Elekta AB, GN Store Nord, Carl Zeiss, and Ondal Medical Systems. Senzime CEO Philip Siberg expressed high expectations for Dr. Reim's expertise in global commercialization and medical technologies, which are anticipated to support the company's rapid growth objectives.

The annual general meeting of Senzime AB was held on May 16, 2024, in Uppsala. Key resolutions include the adoption of the income statement and balance sheet for 2023, with no dividends to be paid. Discharge from liability was granted to board members and the managing director. Remuneration was set, with the chairman receiving SEK 450,000 and the auditor paid per approved invoice. The board will consist of six directors, and PricewaterhouseCoopers was re-elected as auditor. An employee stock option program for 2024/2028 was introduced, and the board was authorized to issue new shares to facilitate the acquisition of Respiratory Motion. Additionally, the board was authorized to increase the company's share capital by up to 20% until the next annual general meeting.

Senzime AB reported a 66% increase in net sales for January - March 2024, with sales of instruments up by 41% and disposables up by 89%. The gross margin decreased to 64.3%, EBITDA improved, but profit after financial items showed a loss. Cash and cash equivalents increased to TSEK 116,856. The company secured a significant deal in the US and saw growth in Japan and South Korea. CEO Philip Siberg highlighted the strong sales growth and emphasized the focus on building a market-leading position. The future outlook remains optimistic with high demand in the market.